Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02505542 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo
A Phase 3 study, sponsored by UCB Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 736
- Enrollment target
NCT02505542 is a Phase 3 study that has completed, run by UCB Biosciences. The registered enrollment target is 736 participants.
The verdict
NCT02505542, a Phase 3 study, has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 736 participants
- Enrollment target
Study Summary
Patients receive study drug for one year (Part A). If, after the initial run-in phase, a sustained remission is reached they will be randomly split into one of three dose groups for another year (Part B). The maintenance of the sustained remission will be analyzed.
Interventions
- OTHER Placebo
- BIOLOGICAL Certolizumab Pegol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 736 participants |
| Start Date | 2015-07 |
| Est. Completion | 2019-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02505542
The ClinicalTrials.gov registry entry for NCT02505542 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 736 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biosciences, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02505542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02505542 about?
NCT02505542 is a clinical study titled "Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo". Patients receive study drug for one year (Part A). If, after the initial run-in phase, a sustained remission is reached they will be randomly split into one of three dose groups for another year (Part B). The maintenance of the sustained remission will be analyzed.
What is the current status of trial NCT02505542?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 736 participants. The study started on 2015-07. Estimated completion is 2019-04.
What interventions are being tested in trial NCT02505542?
The interventions under investigation include: Placebo (OTHER), Certolizumab Pegol (BIOLOGICAL).
Who is sponsoring clinical trial NCT02505542?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.